期刊文献+

富马酸酮替芬分散片在健康人体的药动学及生物等效性评价 被引量:2

Assessment of pharmacokiretics and bioequivalnce of ketotifen fnmarate in healthy volunteers
下载PDF
导出
摘要 目的 :研究富马酸酮替芬分散片在健康人体的药代动力学特征及其生物等效性评价 .方法 :12名健康志愿受试者 ,采用标准二阶段交叉设计试验方法 ,分别单剂量po富马酸酮替芬分散片 (受试品 )和富马酸酮替芬片 (参比品 ) 2mg,以液相色谱 质谱 质谱联用法测定服药后 36h内不同时刻的血药浓度 ,计算主要药动学参数 ,并采用双单侧t检验和 90 %置信区间进行生物等效性评价 .结果 :受试者分别po受试品和参比品后 ,两者主要药动学参数tmax,cmax,t1/ 2 和AUC(0 -3 6h) 分别为 :(2 .7± 1.2 )和 (3.1± 1.4 )h;(4 0 7± 14 7)和(389± 16 8)ng/L ;(5 .5± 1.6 )和 (5 .7± 2 .6 )h ;(2 90 0± 10 4 3)和(2 76 3± 977)ng/(h·L) ,受试品的相对生物利用度为 (112±39) % .结论 :富马酸酮替芬分散片和普通片剂相比 ,具有吸收快、生物利用度较高的优点 ;统计学结果表明 ,两种制剂具有生物等效性 (P <0 .0 5 ) . AIM: To investigate the pharmacokinetics and bioequivalence of ketotifen fumarate in healthy volunteers. METHODS: A single oral dose of the tested and control ketotifen fumarate was given respectively to 12 healthy volunteers in a randomized two-period crossover study. The serum concentration of the two drugs was determined at different time points within 36 hours following the administration by liquid chromatographic-mass spectrometric. The main pharmacokinetics parameters were calculated and the bioequivalence was evaluated by two one-side t test and 90% confidence intervals. RESULTS: The main pharmacokinetics parameters were t max : (2.7±1.2) and (3.1±1.4)h, c max : (407±147)and(389±168)ng/L, t 1/2 :(5.5±1.6)and(5.7±2.6)h, and AUC:(2900±1043)and(2763±977) ng/(h·L). The relative bioavailability of the tested drug was (112±39)%. CONCLUSION: Compared with the control, tested ketotifen fumarate has the advantages of faster absorption and higher bioavailability. The results of statistical analysis indicate that the two drugs are bioequivalent in healthy volunteers (P<0.05).
出处 《第四军医大学学报》 北大核心 2004年第18期1670-1672,共3页 Journal of the Fourth Military Medical University
关键词 富马酸酮替芬 色谱法 液相 光谱分析 质理 药代动力学 生物利用度 ketotifen fumarate chromatography, liquid spectrum analysis, mass Pharmacokinetics biological availalility
  • 相关文献

参考文献5

二级参考文献14

共引文献34

同被引文献15

  • 1钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量:581
  • 2Gran SM,Goa KL,Fitton A.Ketotifen,A review of its pharmacodynamic and pharmacokinctics properties.and therapeutic use in asthma and allersic disorders[J].Drugs,1990;40:412-448.
  • 3Grannen A,Lonnebo A,Beck O.Pharmacokinetics of Ketotifen after oral administration to healthy male subjects[J].Biopharm Drug Dispos,2002;13:255-262.
  • 4GRANNEN A, LONNEBO A, BECK O. Pharmaco- kinetics of Ketotifen after oral administration to healthy male subjects[J]. Biopharm Drug Dispos, 2002,13(4) : 255-262.
  • 5SINGHVI I, SACHDEVA D. Spectrophotometric es- timation of ketotifen fumarate from tablet formulations[J]. Indian Journal of Pharmaceutical Sciences, 2009, 71(1) :66-68.
  • 6KHATER M M, ISSA Y M, SABREIN H, et al. Flow injection determination of ketotifen fumarate u sing PVC membrane selective electrodes[J]. Bioelec trochemistry, 2009,77(1) : 53 -59.
  • 7FLETCHER P, ANDREW K N, CALOKERINOS A C, et al. Analytical applications of flow injection with chemiluminescence detection[J]. Luminescence, 2001, 16(1) : 1-23.
  • 8NIE Fei, LU Jiu-ru. Determination of ketotifen by u- sing calcein as chemiluminescence reagent[J]. Anal Chin Acta, 2007,592(2) : 168-172.
  • 9WHITE E H, BURSEY M M. Chemiluminescence of luminol and related hydrazides: the light emission step[J]. J Am Chem Soc, 1964,86:941 942.
  • 10陈江涛,廖强.反相高效液相色谱法测定富马酸酮替芬滴鼻液的含量[J].中国药业,2011,20(9):23-24. 被引量:4

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部